Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 7459.T and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 7459.T and 80,000+ other tickers.
See exactly how 7459.T's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 7459.T and 80,000+ other tickers.
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including medical equipment, materials, and clinical diagnostic reagents, utilized across diagnostics, testing, treatment, and administration, often from the pre-symptomatic stage. It also offers contract-based post-marketing surveillance (PMS) services to manufacturers and strategically invests in products like orphan drugs. Beyond pharmaceuticals, Medipal…
No recent news available.